Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE 3 cardiovascular outcomes trial of CagriSema in established cardiovascular disease
2023-506924-94-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of cagrilintide and semaglutide in cardiac morbidity, obesity, Overweight and 1 more (2 arms), sponsored by Novo Nordisk. Planned start Feb 2023; status: authorised.
02
Drugs
cagrilintidesemaglutide
03
Conditions
cardiac morbidityobesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-506924-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506924-94-00.